Results 61 to 70 of about 457,015 (304)

Non-organ-specific autoantibodies with unspecific patterns are a frequent para-infectious feature of chronic hepatitis D

Frontiers in Medicine, 2023
Infections with hepatotropic viruses are associated with various immune phenomena. Hepatitis D virus (HDV) causes the most severe form of viral hepatitis.
Lennart Hermanussen, Sibylle Lampalzer, Jan-Hendrik Bockmann, Jan-Hendrik Bockmann, Annerose E. Ziegler, Felix Piecha, Felix Piecha, Maura Dandri, Maura Dandri, Sven Pischke, Sven Pischke, Friedrich Haag, Ansgar W. Lohse, Ansgar W. Lohse, Marc Lütgehetmann, Marc Lütgehetmann, Christina Weiler-Normann, Christina Weiler-Normann, Julian Schulze zur Wiesch, Julian Schulze zur Wiesch, Julian Schulze zur Wiesch   +20 more
doaj   +1 more source

Liver pathology in rural south-west Cameroon [PDF]

, 2017
In a prospective study, 102 hospital patients with liver disease were evaluated in West Cameroon, Africa. Blood donors, pregnant women and patients without liver disease served as controls.
Bianchi, L., Joller-Jemelka, H.I., Knoblauch, M., Skalsky, J.A.   +3 more
core  

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents [PDF]

, 2014
Hepatitis C virus (HCV) is transmitted between hepatocytes via classical cell entry but also uses direct cell-cell transfer to infect neighboring hepatocytes.
A Owsianka, A Sigal, Aleem Siddiqui, Arvind H. Patel, AS Lok, AW Tarr, B Bartolini, B Sainz Jr, C Hezode, C Lee, C Nathan, C Sarrazin, CL Brimacombe, CM Lange, CT Jones, D Masson, D Trono, EJ Gane, Eric Soulier, F Kuonen, F Poordad, F Poordad, Fei Xiao, François Habersetzer, G Koutsoudakis, H Kwon, H Yan, H Zhu, Heidi Barth, I Fofana, I Fofana, I Fofana, IA Abela, IM Jacobson, Isabel Fofana, J Grove, J Lupberger, J Witteveldt, J Zhong, Jens Bukh, JG McHutchison, JM Gottwein, JM Gottwein, JM Pawlotsky, JM Pawlotsky, JM Pawlotsky, JM Timpe, L Rong, L Zona, Laura Heydmann, LW Meredith, MB Zeisel, MB Zeisel, Michel Doffoël, Mirjam B. Zeisel, MN Zahid, MS Sulkowski, MT Catanese, N Shi, O Lenz, P Zhong, PM Trembling, Q Sattentau, S Haid, T Pietschmann, T Pietschmann, T Wakita, Thomas F. Baumert, TJ Liang, TK Scheel, V Soriano, VD Cataldo, ZY Keck   +72 more
core   +7 more sources

Expanding Chemical Space of Nucleic Acid Nanoparticles for Tunable Antiviral‐Like Immunomodulatory Responses and Potent Adjuvant Activity

Advanced Functional Materials, EarlyView.
We introduce a nucleic acid nanoparticle (NANP) platform designed to be rrecognized by the human innate immune system in a regulated manner. By changing chemical composition while maintaining constant architectural parameters, we identify key determinants of immunorecognition enabling the rational design of NANPs with tunable immune activation profiles
Martin Panigaj, Hannah S. Newton, Jian Wang, Laxmi Pandey, Yelixza I. Avilla, Phong Nguyen, Morgan Chandler, Justin Halman, Yasmine Radwan, Stephanie Smith, Elijah Edmondson, Simone Difilippantonio, Chelsea Sanders, Bao Tran, Yongmei Zhao, Shaojun Xie, Edward Cedrone, Barry W. Neun, Meni Wanunu, Nikolay V. Dokholyan, Marina A. Dobrovolskaia, Kirill A. Afonin   +21 more
wiley   +1 more source

Point-of-Care Testing for Hepatitis Viruses: A Growing Need

Life, 2023
Viral hepatitis, caused by hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), or hepatitis E virus (HEV), is a major global public health problem.
Matthew D. Pauly, Lilia Ganova-Raeva
doaj   +1 more source

The V5A13.1 envelope glycoprotein deletion mutant of mouse hepatitis virus type-4 is neuroattenuated by its reduced rate of spread in the central nervous system. [PDF]

, 1992
Following intracerebral inoculation of adult Balb/c Byj mice, the MHV-4 strain of mouse hepatitis virus (MHV) had an LD50 of less than 0.1 PFU, whereas its monoclonal antibody resistant variant V5A13.1 had an LD50 of 10(4.2) PFU.
Bloom, F, Buchmeier, MJ, Fazakerley, JK, Parker, SE   +3 more
core   +1 more source

Nano‐ and Micro‐Sized Solid Materials Used as Antiviral Agents

Advanced Functional Materials, EarlyView.
Due to the rise of viral infections in humans and possible viral outbreaks, the use of nano‐ or micro‐sized materials as antiviral agents is rapidly increasing. This review explores their antiviral properties against RNA and DNA viruses, either as a prevention or a treatment tool, by delving into their mechanisms of action and how to properly assess ...
Orfeas‐Evangelos Plastiras, Imelda Raczkiewicz, Peggy Bouquet, Jean‐Philippe Dacquin, Jeremy Dhainaut, Anne Goffard, Christophe Volkringer   +6 more
wiley   +1 more source

A review of the evidence for the effectiveness of primary prevention interventions for Hepatitis C among injecting drug users [PDF]

, 2006
BACKGROUND Hepatitis C (HCV) prevalence is most common amongst injecting drug users where up to 98% of the population can be infected despite a low prevalence of HIV.
Tompkins, C.N.E., Wright, N.M.J.
core   +3 more sources

Evaluating the Antiviral Efficacy of Encapsulated PKC Inhibitor BIM‐I against influenza A Virus Infection

Advanced Healthcare Materials, EarlyView.
This study explores nanoparticle delivery of the protein kinase C inhibitor bisindolylmaleimide‐I (BIM‐I) to combat influenza A virus infections. Encapsulation in biodegradable PLGA nanoparticles improved safety while maintaining the compound's strong antiviral activity.
Laura Klement, Jana Ismail, Josefine Schroeder, Amod Godbole, Johanna Schreiber, Christine Weber, Zoltan Cseresnyes, Marc T. Figge, Bettina Löffler, Ulrich S. Schubert, Stephanie Schubert, Christina Ehrhardt, Carsten Hoffmann   +12 more
wiley   +1 more source

Vacunas de las hepatitis viricas: de la A a la E [PDF]

, 2011
En los últimos cuarenta años el desarrollo del conocimiento de los virus causantes de hepatitis ha sido impresionante y hoy DIAGNOSTICAMOS al menos cinco tipos de virus, dos de transmisión oral y tres de transmisión parenteral y sexual( Figura 1 ).Estos ...
Rodrigo Gómez, José Manuel
core